Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial

Libby, 2005, The forgotten majority: unfinished business in cardiovascular risk reduction., J Am Coll Cardiol, 46, 1225, 10.1016/j.jacc.2005.07.006

Gordon, 1989, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies., Circulation, 79, 8, 10.1161/01.CIR.79.1.8

Barter, 2007, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events., N Engl J Med, 357, 1301, 10.1056/NEJMoa064278

Nicholls, 2005, Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits., Arterioscler Thromb Vasc Biol, 25, 2416, 10.1161/01.ATV.0000184760.95957.d6

Badimon, 1990, Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit., J Clin Invest, 85, 1234, 10.1172/JCI114558

Badimon, 1989, High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits., Lab Invest, 60, 455

Boden, 2011, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy., N Engl J Med, 365, 2255, 10.1056/NEJMoa1107579

Keene, 2014, Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients., BMJ, 349, g4379, 10.1136/bmj.g4379

Toth, 2014, Should low high-density lipoprotein cholesterol (HDL-C) be treated?, Best Pract Res Clin Endocrinol Metab, 28, 353, 10.1016/j.beem.2013.11.002

Landray, 2014, Effects of extended-release niacin with laropiprant in high-risk patients., N Engl J Med, 371, 203, 10.1056/NEJMoa1300955

Ginsberg, 2010, Effects of combination lipid therapy in type 2 diabetes mellitus., N Engl J Med, 362, 1563, 10.1056/NEJMoa1001282

Keech, 2005, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial., Lancet, 366, 1849, 10.1016/S0140-6736(05)67667-2

Angelin, 2002, Reverse cholesterol transport in man: promotion of fecal steroid excretion by infusion of reconstituted HDL., Atheroscler Suppl, 3, 23, 10.1016/S1567-5688(02)00047-8

Michael Gibson, 2016, Safety and tolerability of CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I, after acute myocardial infarction: the AEGIS-I trial (ApoA-I Event Reducing in Ischemic Syndromes I)., Circulation, 134, 1918, 10.1161/CIRCULATIONAHA.116.025687

Spieker, 2002, High-density lipoprotein restores endothelial function in hypercholesterolemic men., Circulation, 105, 1399, 10.1161/01.CIR.0000013424.28206.8F

Bisoendial, 2003, Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein., Circulation, 107, 2944, 10.1161/01.CIR.0000070934.69310.1A

Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial., JAMA, 290, 2292, 10.1001/jama.290.17.2292

Kempen, 2016, High-density lipoprotein subfractions and cholesterol efflux capacities after infusion of MDCO-216 (apolipoprotein a-imilano/palmitoyl-oleoyl-phosphatidylcholine) in healthy volunteers and stable coronary artery disease patients., Arterioscler Thromb Vasc Biol, 36, 736, 10.1161/ATVBAHA.115.307052

Kallend, 2016, A single infusion of MDCO-216 (ApoA-1 Milano/POPC) increases ABCA1-mediated cholesterol efflux and pre-beta 1 HDL in healthy volunteers and patients with stable coronary artery disease., Eur Heart J Cardiovasc Pharmacother, 2, 23, 10.1093/ehjcvp/pvv041

Reijers, 2017, MDCO-216 does not induce adverse immunostimulation, in contrast to its predecessor ETC-216., Cardiovasc Drugs Ther, 31, 381, 10.1007/s10557-017-6746-x

Nissen, 2004, Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial., JAMA, 291, 1071, 10.1001/jama.291.9.1071

Nissen, 2006, Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial., JAMA, 295, 1556, 10.1001/jama.295.13.jpc60002

Nissen, 2008, Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial., JAMA, 299, 1561, 10.1001/jama.299.13.1561

Nissen, 2008, Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial., JAMA, 299, 1547, 10.1001/jama.299.13.1547

Nissen, 2007, Effect of torcetrapib on the progression of coronary atherosclerosis., N Engl J Med, 356, 1304, 10.1056/NEJMoa070635

Nissen, 2006, Effect of ACAT inhibition on the progression of coronary atherosclerosis., N Engl J Med, 354, 1253, 10.1056/NEJMoa054699

Nissen, 2004, Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial., JAMA, 292, 2217, 10.1001/jama.292.18.2217

Nicholls, 2011, Effect of two intensive statin regimens on progression of coronary disease., N Engl J Med, 365, 2078, 10.1056/NEJMoa1110874

Nicholls, 2016, Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial., JAMA, 316, 2373, 10.1001/jama.2016.16951

Bowman, 2017, Effects of anacetrapib in patients with atherosclerotic vascular disease., N Engl J Med, 377, 1217, 10.1056/NEJMoa1706444

Khera, 2011, Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis., N Engl J Med, 364, 127, 10.1056/NEJMoa1001689

Rong, 2001, Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content., Circulation, 104, 2447, 10.1161/hc4501.098952

Feig, 2011, HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells., Proc Natl Acad Sci U S A, 108, 7166, 10.1073/pnas.1016086108

Nicholls, 2010, Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome., J Am Coll Cardiol, 55, 2399, 10.1016/j.jacc.2010.02.026

Sabatine, 2017, Evolocumab and clinical outcomes in patients with cardiovascular disease., N Engl J Med, 376, 1713, 10.1056/NEJMoa1615664